NASDAQ:AMRSAmyris Stock Price, Forecast & News

Amyris' stock was trading at $2.96 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AMRS shares have increased by 18.9% and is now trading at $3.52.
View which stocks have been most impacted by COVID-19.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amyris in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Amyris.

Amyris is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Amyris.

Amyris Inc (NASDAQ:AMRS) released its earnings results on Thursday, August, 6th. The biotechnology company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.19) by $0.37.
View Amyris' earnings history.

Amyris shares reverse split on the morning of Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2017. An investor that had 100 shares of Amyris stock prior to the reverse split would have 7 shares after the split.

Amyris issued an update on its FY 2020 Pre-Market earnings guidance on Thursday, August, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $220.32-220.32 million, compared to the consensus revenue estimate of $220.6 million.

2 Wall Street analysts have issued 12 month price targets for Amyris' shares. Their forecasts range from $9.00 to $11.00. On average, they anticipate Amyris' share price to reach $10.00 in the next twelve months. This suggests a possible upside of 184.1% from the stock's current price.
View analysts' price targets for Amyris.

News headlines about AMRS stock have trended negative on Thursday, InfoTrie Sentiment reports. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Amyris earned a news impact score of -2.4 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days.
View the latest news about Amyris.

Some companies that are related to Amyris include Phillips 66 (PSX), Marathon Petroleum (MPC), Valero Energy (VLO), HollyFrontier (HFC), CVR Energy (CVI), World Fuel Services (INT), Renewable Energy Group (REGI), PBF Energy (PBF), Delek US (DK), Clean Energy Fuels (CLNE), Green Plains (GPRE), REX American Resources (REX), Adams Resources & Energy (AE) and Gevo (GEVO).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amyris investors own include Advanced Micro Devices (AMD), General Electric (GE), Gevo (GEVO), Inovio Pharmaceuticals (INO), Nokia Oyj (NOK), AT&T (T), Pfizer (PFE), Sorrento Therapeutics (SRNE), Exxon Mobil (XOM) and Novavax (NVAX).

Amyris trades on the NASDAQ under the ticker symbol "AMRS."

Amyris' stock is owned by many different institutional and retail investors. Top institutional shareholders include FMR LLC (10.97%), Hudson Bay Capital Management LP (1.55%), Monashee Investment Management LLC (0.34%), Bank of New York Mellon Corp (0.15%), Virtu Financial LLC (0.14%) and Goldman Sachs Group Inc. (0.14%). Company insiders that own Amyris stock include Eduardo Alvarez, Frank Kung, John Melo, Kathleen Valiasek, L John Doerr and Patrick Y Yang.
View institutional ownership trends for Amyris.

AMRS stock was sold by a variety of institutional investors in the last quarter, including Hudson Bay Capital Management LP, Essex Investment Management Co. LLC, UBS Group AG, Spark Investment Management LLC, Virtus ETF Advisers LLC, and Envestnet Asset Management Inc.. Company insiders that have sold Amyris company stock in the last year include John Melo, and Patrick Y Yang.
View insider buying and selling activity for Amyris.

AMRS stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Monashee Investment Management LLC, Virtu Financial LLC, Algert Global LLC, Skandinaviska Enskilda Banken AB publ , California Public Employees Retirement System, Swiss National Bank, and Goldman Sachs Group Inc.. Company insiders that have bought Amyris stock in the last two years include Eduardo Alvarez, Frank Kung, Kathleen Valiasek, L John Doerr, and Patrick Y Yang.
View insider buying and selling activity for Amyris.

Shares of AMRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AMRS stock can currently be purchased for approximately $3.52.

Amyris has a market capitalization of $573.95 million and generates $152.56 million in revenue each year. The biotechnology company earns $-242,770,000.00 in net income (profit) each year or ($2.72) on an earnings per share basis. Amyris employs 414 workers across the globe.

The official website for Amyris is amyris.com.

Amyris' mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-450-0761 or via email at [email protected]